RT Journal Article
SR Electronic
T1 Clinical Characteristics and Outcomes of Laboratory-Confirmed SARS-CoV-2 Cases Infected with Omicron subvariants and XBB recombinant variant
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.01.05.23284211
DO 10.1101/2023.01.05.23284211
A1 Karyakarte, Rajesh
A1 Das, Rashmita
A1 Dudhate, Sonali
A1 Agarasen, Jeanne
A1 Pillai, Praveena
A1 Chandankhede, Priyanka
A1 Labshetwar, Rutika
A1 Gadiyal, Yogita
A1 Rajmane, Mansi
A1 Kulkarni, Preeti
A1 Nizarudeen, Safanah
A1 Joshi, Suvarna
A1 Potdar, Varsha
A1 Karmodiya, Krishanpal
YR 2023
UL http://medrxiv.org/content/early/2023/01/27/2023.01.05.23284211.abstract
AB Background SARS-CoV-2 has evolved to produce new variants causing successive waves of infection. Currently, six variants are being monitored by the World Health Organization that are replacing BA.5. These include BF.7 (BA.5 + R346T in spike), BQ.1 (and BQ.1.1, with BA.5 + R346T, K444T, N460K mutations in spike), BA.2.75 (including BA.2.75.2 and CH.1.1), and XBB (including XBB.1.5). BQ.1 and XBB variants are more immune evasive and have spread quickly throughout the world. With the concern of the potential severity of infections caused by these variants, the present study describes the clinical characteristics and outcomes of these major variants in Maharashtra.Material and Methods A total of 1141 Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) positive SARS-CoV-2 samples, with a cycle threshold value (Ct) less than 25, were processed for SARS-CoV-2 whole genome sequencing between 10th July 2022 and 12th January 2023. All corresponding demographic and clinical data were recorded and analysed using Microsoft® Excel and Epi Info™.Results Out of 1141 samples sequenced, BA.2.75* (63.78%) was the predominant Omicron variant, followed by the XBB* (18.88%), BA.2.38* (4.94%), BA.5* (4.06%), BA.2.10* (3.51%) and BQ.1* (1.65%). A total of 540 cases were contacted telephonically, of which 494 (91.48%) were symptomatic with mild symptoms. Fever (77.73%) was the most common symptom, followed by cold (47.98%), cough (42.31%), myalgia and fatigue (18.83%). Of the 540 cases, 414 (76.67%) cases recovered at home, and 126 (23.33%) were institutionally quarantined/hospitalised. Among the home-isolated and hospitalised cases, 416 (99.76%) and 108 (87.80%), respectively, recovered with symptomatic treatment, while one (0.24%) and 15 (12.20%), respectively, succumbed to the disease. In all, 491 (90.93%) cases were vaccinated with at least one dose of the COVID-19 vaccine, 41 (7.59%) were unvaccinated, and for 08 (1.48%), vaccine data was not available.Conclusion The current study indicates that the XBB* variant is causing mild disease in India. However, as XBB* possess both immune-escape and infectivity-enhancing mutations, it has the potential to spread to other parts of the world rapidly.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Ethics Committee of B.J. G. Medical College and Sassoon General Hospitals, Pune 1 gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript.